Investor Presentaiton
Novo Nordisk Annual Report 2023
ESG initiatives (continued)
Agenda
Access and
affordability
(continued)
Name
MyInsulinRx™
Introducing Novo Nordisk Strategic Aspirations
Risks
Management
Consolidated statements
Additional information
103
Provide access to affordable insulin to those in need
in the US.
2023 Progress
We replaced My99Insulin with MyInsulinRxTM, reducing the out of pocket cost for
patients from USD 99 to 35.
Description
Reach
Ambition
Programme allowing eligible patients to obtain a monthly supply of any combination of Novo Nordisk insulin products
(up to three vials or two packs of pens) for USD 35.
US16
Patient Assistance
Program
Programme offering free diabetes medication to people in need who meet certain eligibility criteria, including annual
household income at or below 400% of the government-defined poverty level.
US
Immediate Supply
Program
Programme providing a free, one-time, short-term supply of our insulin (up to three vials or two packs of pens) to eligible
patients who may be at risk of rationing.
US
Copay Savings Offers
Offers reducing the cost for commercially insured patients who are exposed to higher than average copays.
US
Prevention
Cities Changing Diabetes
Programme bringing together a network of 47 city-based public-private partnerships that aim to prevent obesity and type 2
diabetes in vulnerable populations and children.
Global
Partnership with UNICEF
Collaboration aiming to prevent childhood obesity across Latin America and Asia Pacific. It uses policies, programmes and
practices to directly impact the nutrition, wellbeing and development of children.
MX17, CO18,
BR, ID19
inclusion
S Diversity and
leave policy
Global parental
Policy offering a minimum of eight weeks of paid leave within the first year of becoming a parent to all non-birthing parents
globally, regardless of gender.
Global
Global inclusion index
Numerical indicator, included in our annual employee engagement survey, of how employees rate the state of inclusion in
Novo Nordisk. It includes four statements covering psychological safety, equal opportunity, sense of belonging and valuing
of diverse perspectives.
Global
Yearly equal pay reviews
Equal pay reviews conducted on a yearly basis and followed by corrective actions for confirmed equal pay risk cases.
Global,
excluding US
Gender diversity targets
Two aspirational gender diversity targets that accelerate progress towards balanced gender representation and ensure
leadership accountability.
Global
G Company
culture
Novo Nordisk
Way Facilitation
Collaborative assessment that a team of facilitators performs with selected units to evaluate their compliance with the Novo.
Nordisk Way.
Global
G Ethics and
Global Ethics and
compliance
Compliance Framework
The Novo Nordisk Way, our OneCode and international and local standards for responsible business conduct set the foundation
for ethics and compliance in Novo Nordisk. This covers anti-fraud, anti-bribery, anti-off-label promotion, transparency in dealing
with healthcare professionals and organisations, protection of personal data and respect to human rights.
Global
Annual Ethics and
Compliance Training
Ethics and compliance training conducted on an annual basis and mandatory for all employees, including all new hires.
Global
Business Ethics Reviews
Business ethics reviews performed by Group Internal Audit (GIA) in subsidiaries, production sites, vendors and headquarters
to assess the level of ethics and compliance in Novo Nordisk.
Global
16. US: United States. 17. MX: Mexico. 18. CO: Colombia. 19. ID: Indonesia.
Provide access to affordable diabetes medication to
those in need in the US.
Provide access to affordable insulin to those in need
in the US.
We provided free insulin to 63 thousand people and free GLP-1-based medicines to 162
thousand people.
Nine thousand patients had access to this programme, and we provided education on
availability of our affordability offerings.
Provide access to affordable diabetes medication to
those in need in the US.
We provided USD 169 million in copay assistance for insulin and USD 599 million in
copay assistance for GLP-1-based medicines.
Promote health equity, expand prevention efforts
and address barriers to health for vulnerable
populations and children.
Directly impact at least 10 million children through
programmatic activities by 2026.
Ensure that all employees get the opportunity to
bond with their child.
Over 50 research studies were conducted, more than 250 local partnerships were
created or strengthened, and over 85 local interventions on diabetes and obesity were
initiated.
So far, the partnership has benefitted more than 2.7 million children and caregivers.
across Latin America and the Caribbean through direct programmatic reach.
Employees worldwide continue to benefit from our enhanced parental leave policy.
Sustain progress on the state of inclusion in
Novo Nordisk.
Of the more than 47,000 employees who completed the survey, 82% rated the inclusion
statements favourable, compared to 78% in 2021 and 82% in 2022.
Mitigate bias in pay processes and decisions.
Achieve a balanced gender representation across all
managerial levels and a minimum of 45% women
and 45% men in senior leadership positions by the
end of 2025.
Assess all high-risk units yearly.
Ensure that all Novo Nordisk employees act with
integrity and in compliance with the ethics and
compliance framework.
Train all Novo Nordisk employees annually in ethics
and compliance.
Complete 45 business ethics reviews in 2024.
Out of the more than 49,000 positions covered in the pay review, we identified 0.6%
with an equal pay gap and we are taking corrective actions.
By end of year, 46% of all leaders were women, and 41% of leaders in senior leadership
positions were women, compared to 44% and 39%, respectively, at the end of 2022.
42 units were assessed, one of which was deemed to not be working in accordance
with the Novo Nordisk Way. The most frequent findings raised to management teams
relate to ambition, empowerment, stakeholder relations, simplicity or agility.
We launched OneCode, which sets expectations and guides all Novo Nordisk employees
on how we act as a company and individuals.
99% of all employees completed and documented their training, with the remaining 1%
missing mainly due to employees being on leave.
40 business ethics reviews were completed, compared to 35 reviews in 2022. Consolidated
conclusions were reported to Executive Management and the Audit Committee. GIA
assessed that the level of ethics and compliance in Novo Nordisk is sound.View entire presentation